Abivax to Participate in Upcoming Fall Investor Conferences

PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences:

Guggenheim Healthcare Innovation Conference
Boston, Massachusetts
November 9-11, 2026
Fireside Chat: Tuesday, November 10^th, 10:30-10:55am ET

LifeSci Capital X Sofinnova Growth & Innovation Summit
London, United Kingdom
November 16, 2026

30^th German Equity Forum (Deutsches Eigenkapitalforum)
Frankfurt, Germany
November 23-25, 2026
Corporate Presentation: Monday, November 23^rd, 11:40am-12:10pm CET

Evercore ISI 9^th Annual Healthcare Conference
Miami, Florida
November 30 – December 2, 2026
Fireside Chat: Wednesday, December 2^nd, 7:55-8:15am ET

Piper Sandler 38^th Annual Healthcare Conference
New York, New York
December 1-3, 2026
Fireside Chat: Thursday, December 3^rd, 8:00-8:25am ET

Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Abivax SA
Patrick Malloy
SVP, Investor Relations
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

aap Implantate AG: Focus on the trauma business – fully MDR-certified portfolio, new products, expanded sales activities – capital increase to finance the next phase of growth

• Capital increase with subscription rights for up to 1,486,563 new shares at EUR 1.35 per share
• Subscription period from November 6 to 20, 2026; oversubscription permitted
• Full MDR certification of the existing portfolio completed as of March 2026
• Revenue performance improved significantly over the course of the year; Q3 2026 saw slight year-over-year growth
• EBITDA continued to improve in the first nine months of 2026
• US business continues to grow at a double-digit rate on a high comparative basis
• New products already on the market; additional product launches planned through 2028
• Sales organization restructured and strengthened internationally
• New management team, led by COO Cornelius Fink and CFO Nicole Kassel, focuses on sales, efficiency, and cost discipline
• 2026 forecast confirmed

Berlin, November 2, 2026 – The Management Board of aap Implantate AG (“aap”, ISIN: DE000A3H2101), a manufacturer of “Made in Germany” trauma implants, today resolved — with the approval of the Supervisory Board – to conduct a capital increase against cash contributions with subscription rights from the 2024/I authorized capital (see today’s ad hoc announcement). The share capital is to be increased from EUR 14,716,976.00 by up to EUR 1,486,563.00 to a maximum of EUR 16,203,539.00. The new shares will be offered at a ratio of 9.9:1 at a subscription price of EUR 1.35 and will be entitled to dividends as of January 1, 2026. aap intends to use the proceeds from the offering to strengthen its liquidity base and finance the next phase of growth in the trauma business. In addition, the company plans to convert shareholder loans totaling EUR 1,700,000 into equity. To further strengthen the Company’s equity base, the Management Board also intends, subject to the approval of the Supervisory Board, to increase the Company’s share capital by up to EUR 1,350,000.00 (approximately 9% of the currently existing share capital) against contributions in kind, excluding shareholders’ subscription rights. The contribution in kind is intended to comprise shareholder loans granted to the Company with a nominal amount of EUR 1,700,000.00 (debt-to-equity swap). The implementation of the capital increase against contributions in kind is subject to an audit of the contributions in kind by a court-appointed auditor.

The capital increase against contributions in kind is intended to strengthen the Company’s balance sheet structure by increasing equity while simultaneously eliminating the loan liabilities, thereby reducing the interest expense associated with the shareholder loans.

Restructuring and MDR transformation successfully completed

In recent years, aap has fundamentally restructured its business: US sales operations were transitioned to a lean agent model, and the cost structure was significantly optimized across the Group. The Group’s EBITDA loss decreased from EUR 5.1 million in 2019 to EUR 0.64 million in 2025.

A key milestone in the realignment was the transition to the European Medical Device Regulation (MDR). The complex certification process tied up substantial development resources over several years and resulted in non-capitalizable expenses in the seven-figure euro range. The necessary investments and development expenses have largely been completed. As of March 2026, the entire existing product portfolio has been successfully MDR-certified. This means that aap now has the required MDR certification for its entire existing product portfolio, granting it market access in the EU and other CE-relevant markets.

Profitability in the core business has improved significantly – the turnaround in operating performance continued in Q3

The operating performance of aap continued to improve in the first nine months of 2026. While revenue in the first half of 2026 was still 5% below the prior-year figure, this shortfall was significantly reduced in the third quarter.

The operating recovery continued in the third quarter of 2026. Compared to the previous quarter, revenue rose from EUR 2.8 million to EUR 3.3 million, placing it slightly above the level of the same quarter a year earlier. For the first nine months of 2026, this resulted in a revenue decline of only 2.8% compared to the same period a year earlier. This reflects a gradual improvement in revenue performance over the course of the year.

At the same time, the positive earnings trend continued. EBITDA improved once again in the first nine months of 2026 and exceeded the IFRS profitability threshold. This underscores the progress made in efficiency, cost control, and operational performance.

The US business, which is considered a key growth driver for the Group, continued to show particularly strong momentum. In the third quarter of 2025, aap had already posted an exceptionally strong quarter with an 18% increase in revenue compared to the same quarter of the previous year. Against this high comparative base, performance in the third quarter of 2026 improved even further: Revenue in local currency was a further 2% above the strong prior-year quarter. The fourth quarter also began with the highest monthly order intake of the year.

For the first nine months of 2026, revenue in the US increased by 15% in local currency and by 13% on a euro basis. This positive performance confirms the effectiveness of the realignment of the US business and the growing market acceptance of the products. For the first time since its founding, the US subsidiary posted a positive local earnings result.

Additional momentum was evident in July 2026, with the highest order intake recorded in 2026. Management views this as a positive signal for business development in the coming quarters.

There are three clear growth drivers: products, production, and sales

All three growth drivers have already been set in motion; the proceeds from the offering are intended to accelerate their implementation.

Product innovation – attractive market potential: At the end of the second quarter of 2026, aap launched LOQTEQ® VA Elbow, its first fully MDR-certified new product; LOQTEQ® VA Proximal Humerus has received FDA approval. Additional systems are scheduled to follow gradually through 2028, including VA-Tibia & Fibula, VA Foot & Calcaneus, and the CHBS cannulated head screws. Eleven additional development projects are planned through 2031.

Production processes – increased productivity through automation: aap manufactures all its products in Berlin and mills the implants from solid titanium. Through 2028, the company plans to invest in lathes and milling machines, collaborative robotics, and automated material feeding. The goal is to increase capacity and reduce the number of staff required per implant.

Sales – expansion of international sales: In recent months, aap has restructured its sales organization with clearly defined responsibilities and hired additional sales staff. The company is expanding its presence primarily in Spain, Portugal, Chile, and France. In the first half of 2026, sales in Spain and Portugal already grew by more than 30% each thanks to the new VA products. Management sees further growth potential, particularly in North America, as a result of the sales restructuring.

CEO Rubino Di Girolamo: foundation laid for sustainable growth

Rubino Di Girolamo, Chief Executive Officer (CEO) of aap Implantate AG, explains:

“After years of intensive restructuring efforts, we now see, for the first time, that all the key prerequisites for sustainable growth have been met: a fully MDR-certified portfolio, significantly improved operational profitability, new products on the market, and a strengthened international sales organization. The capital increase is intended to enable us to capitalize on these opportunities more quickly and usher in the next phase of aap’s development.”

New management team focuses on growth and profitability

Since August 2026, Cornelius Fink (COO, responsible for Trauma) and Nicole Kassel (CFO, responsible for finance, procurement, and IT) have joined the Management Board, bringing with them experience in production processes, controlling, and transformation projects. Rubino Di Girolamo will smoothly hand over responsibilities to the new team by December 31, 2026, and will remain associated with aap as a consultant thereafter.

Cornelius Fink, member of the Executive Board (COO) of aap Implantate AG, says:

“The new sales team is on board, the first VA products are already on the market, and concrete plans are in place for investments in new machinery. We now intend to use the proceeds from the offering to drive all three growth levers in a targeted and parallel manner.”

Nicole Kassel, member of the Management Board (CFO) of aap Implantate AG, adds:

“The proceeds from the offering are to be directed specifically toward measures that support growth or improve the cost base. In doing so, we consistently evaluate individual measures based on their contribution to operating performance and earnings.”

A certified portfolio in a growing global market

According to industry estimates, the global market for trauma fixation systems is expected to grow from approximately USD 9.6 billion in 2025 to approximately USD 13.4 billion in 2035. The elbow and the foot and ankle are among the fastest-growing indications – precisely the areas that aap is targeting with its new VA systems.

The business model is geared toward recurring revenue: hospitals and distributors make a one-time investment in surgical sets; plates and screws are reordered for each specific surgery. aap holds product registrations in 46 countries and aims for average double-digit annual revenue growth starting in 2027.

Outlook: 2026 forecast confirmed; growth contributions expected starting in 2027

Despite significant losses in the Middle East, the Management Board confirms its forecast for 2026, with revenue of EUR 11.5 million to EUR 14.5 million and EBITDA of EUR -1.0 million to EUR +1.5 million. Regarding EBITDA, the Management Board continues to expect a positive result in the middle of the forecast range. The new products will be introduced gradually and are expected to make a significant contribution to earnings growth starting in 2027.

Rubino Di Girolamo adds:

“With this capital increase, we aim to create the conditions – on a significantly improved operational footing – to finance our next steps toward growth. At the same time, we are enabling our shareholders to maintain their ownership stake through their subscription rights and to participate in the company’s continued development.”

Key details of the subscription offering

The subscription period (indirect subscription rights) is expected to run from November 6 to November 20, 2026. Subscription rights will not be traded; unexercised subscription rights will expire. All shareholders may subscribe for additional shares beyond their subscription rights. Such oversubscription must also be exercised within the subscription period. Shares not subscribed for as part of the capital increase are to be offered to selected investors in a private placement at no less than the subscription price. The subscription offer is expected to be announced in the Federal Gazette on November 4, 2026. The lead underwriter is BankM AG.

About aap Implantate AG

Based in Berlin, aap Implantate AG develops, manufactures, and distributes implants for trauma surgery. At the core of its product portfolio is the patented LOQTEQ® plate system, which combines fracture compression and angle-stable fixation in a single surgical step. All existing products are MDR-certified and are 100% manufactured in Berlin. In Germany, aap sells directly to hospitals and purchasing groups; internationally, it sells through distributors; and in the U.S., it sells through its subsidiary, aap Implants Inc. Product registrations are in place in 46 countries. In addition, aap has a patented antibacterial silver-coating technology that has already passed clinical trials and is seeking approval. The stock is listed on the regulated market of the Frankfurt Stock Exchange (General Standard) (ISIN: DE000A3H2101, WKN: A3H210).

www.aap.de
 

Contact Investor Relations:

CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone: +49 89 125 09 0333
Email: sh@crossalliance.de
www.crossalliance.de

Important notice

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of aap Implantate AG. The offering is governed exclusively by the subscription offer published in the Federal Gazette. This announcement is not intended for publication or distribution in or within the United States of America, Canada, Australia, or Japan. It may contain forward-looking statements based on the current expectations of the Management Board and subject to risks and uncertainties; actual results may differ materially.

aap Implantate AG: Rights issue from authorized capital and intended capital increase against contributions in kind

Berlin, November 2, 2026 – The Management Board of aap Implantate AG (“aap” or the “Company”) today resolved, with the approval of the Supervisory Board, to carry out a capital increase against cash contributions with subscription and oversubscription rights for the Company’s shareholders from Authorized Capital 2024/I. In this context, the share capital of aap is to be increased from currently EUR 14,716,976.00 by up to EUR 1,486,563.00 through the issuance of up to 1,486,563 new no-par value bearer shares to up to EUR 16,203,539.00. The new shares are to be offered to the Company’s shareholders at a subscription ratio of 9.9 to 1 and at a subscription price of EUR 1.35 per new share. The new shares will carry dividend rights from 1 January 2026. Subscription rights for fractional amounts will be excluded.

The proceeds from the transaction are intended to be used to strengthen the liquidity position of aap.

The new shares will be offered to the shareholders of aap for subscription by way of an indirect subscription right during a subscription period. The subscription period is expected to commence on 6 November 2026 at 0:00 CET and to end on 20 November 2026 at 24:00 CET. No trading in subscription rights will be arranged, and any subscription rights not exercised will expire without value. In addition, all shareholders of the Company will have the option to participate in the capital increase beyond the exercise of their subscription rights by way of oversubscription. These oversubscription rights must also be exercised within the subscription period. New shares not subscribed for as part of the rights offering are to be offered to investors by way of a private placement at a price at least equal to the subscription price per new share.

In order to further strengthen the Company’s equity base, the Management Board also intends, with the approval of the Supervisory Board and by making further partial use of Authorized Capital 2024/I or Authorized Capital 2026/I, to increase the Company’s share capital by up to EUR 1,350,000.00 (approximately 9% of the currently existing share capital) against contributions in kind and excluding shareholders’ subscription rights. The contribution in kind is intended to comprise shareholder loans granted to the Company with a nominal amount of EUR 1,700,000.00, which are to be contributed to the Company by way of a debt-to-equity swap in exchange for the issuance of up to a further 1,350,000 new shares. The implementation of the capital increase against contributions in kind requires an audit of the contribution in kind by a court-appointed auditor.

The capital increase against contributions in kind is intended to strengthen the balance sheet structure of aap by increasing equity while simultaneously eliminating the loan liabilities and will result in a reduction of the Company’s interest expense associated with the shareholder loans.

Contact:

For queries, please contact:
aap Implantate AG; R. Di Girolamo; Chairman of the Management Board / CEO; Lorenzweg 5; D-12099 Berlin
Tel.: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de

*****

Immunic to Participate in Investor Conferences in November

NEW YORK, November 2, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November: 

• November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference. Erik Lundgren, Chief Executive Officer, and Jason Tardio, President and Chief Operating Officer, will participate in a fireside chat on Monday, November 9, 2026 at 1:00 pm ET at this conference in Boston. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations. 

Mr. Lundgren, Mr. Tardio, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Guggenheim representative or Jessica Breu at: jessica.breu@imux.com.

• November 10-12: Stifel 2026 Healthcare Conference. Mr. Lundgren and Mr. Tardio will participate in a fireside chat on Wednesday, November 11, 2026 at 2:00 pm ET at this conference in New York. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Mr. Lundgren, Mr. Tardio, and Mrs. Breu will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Stifel representative or Jessica Breu at: jessica.breu@imux.com. 

• November 17-18: Mr. Lundgren, Mr. Tardio, and Patrick Walsh, Chief Business Officer, will be hosting one-on-one meetings in London in connection with the Jefferies Global Healthcare Conference. To schedule a meeting, please contact Jessica Breu at: jessica.breu@imux.com.

Additionally, Immunic will host a Virtual Progressive Multiple Sclerosis R&D Day on Thursday, November 5, 2026 at 12:30 pm ET with management and two renowned experts in the treatment of multiple sclerosis (MS) and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy. The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Register here to attend. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com

•  Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius’ portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales; the largest development agreement announced in the biosimilars industry to date.  

• Agreement gives Fresenius full strategic flexibility to select and advance biosimilar candidates to develop, against its established selection criteria, while retaining full commercialization economics of products under the agreement.  

• Fresenius will determine the long-term manufacturing strategy for each candidate, with optionality to leverage the mAbxience network, wholly owned since October 2026. 

• The next-generation portfolio spans 13 therapeutic areas and multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins.  

Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced that it has entered an exclusive development agreement with WuXi Biologics (2269.HK), a leading global contract organization for research, development and manufacturing. WuXi Biologics brings proven large-scale biologics development and manufacturing capability, a track record across monoclonal and bispecific antibodies and antibody-drug conjugates, and a worldwide network spanning Europe, the United States, China and Singapore. The agreement significantly expands and accelerates Fresenius’ biosimilars pipeline while preserving strategic flexibility and disciplined capital allocation. It provides access to a scalable pathway to increase the portfolio from 29 marketed and pipeline molecules today to up to 66 molecules, addressing more than €370 billion in originator list-price-based-sales, extending Biopharma growth in the long term beyond its 2030 ambition. 

The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates over the next decade, making it the largest development agreement announced in the biosimilars industry to date. Development programs will be selected and advanced against Fresenius’ established selection criteria, based on market attractiveness, development risk, and expected returns. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement.  

Michael Sen, Chief Executive Officer of Fresenius, said: “We are doubling down on our Biopharma business. With this agreement we are gaining access to development capabilities in a market where speed and scale are of the essence. It provides a disciplined, scalable way to potentially triple our portfolio while retaining economic ownership, strategic control and the flexibility to allocate capital to the most compelling opportunities. Combined with the full ownership of mAbxience, this fuels our Biopharma growth well beyond 2030.” 

The next-generation portfolio is expected to span 13 therapeutic areas, including expanding into neurology, nephrology and cardiopulmonary, while further strengthening Fresenius’ established positions in oncology, immunology, and gastroenterology. It will encompass multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, an antibody-drug conjugate for the treatment of diffuse large B-cell lymphoma, and teprotumumab, a monoclonal antibody for the treatment of thyroid eye disease. 

The agreement forms part of a balanced pipeline expansion strategy through internal R&D, targeted collaboration, and selective in-licensing. It gives Fresenius privileged access to the rapidly advancing biotech landscape worldwide and combines this with Fresenius’ global manufacturing and commercialization network. Development activities are expected to be conducted using WuXi Biologics’ global network. Building on the recent acquisition of Spain-headquartered mAbxience, the agreement significantly expands the funnel of potential development candidates for Fresenius’ wholly owned platform, enabling greater value capture across the development, manufacturing and commercialization value chain.  

Financial Considerations 

Fresenius’ full-year 2026 guidance remains unchanged, and the company confirms the 2030 Biopharma ambition announced in December 2025 of – approximately doubling Biopharma revenue compared with 2025 at an EBIT margin of around 20% – which relates to the existing marketed and late-stage portfolio. The agreement is additive, expanding the opportunity beyond 2030, and, as a result, Fresenius expects to raise its long-term Biopharma ambitions significantly.  

Under the terms of the agreement, Fresenius will compensate WuXi Biologics on a fee-for-service basis for each biosimilar candidate that Fresenius selects for development. Research and development investment scales only as selected programs progress, with each option exercised against Fresenius’ established selection criteria (market attractiveness, development risk, and expected returns). Fresenius will determine the long-term manufacturing strategy for each biosimilar candidate, including the potential progressive transfer of selected products to mAbxience. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement. 

As selected candidates advance, Biopharma research and development expenditure and profitability will correspondingly reflect the increased level of investment during the development phase, ahead of future revenue and profitability growth.  

The agreement fits within Fresenius’ unchanged financial framework, with continued priority on a strong balance sheet and further deleveraging; it is funded from operating cash flow and requires no new financing. Fresenius is rated BBB with a positive outlook by S&P, Baa3 with a stable outlook by Moody’s, and BBB- with a positive outlook by Fitch. 

# # # 

Related Publications 

The 1 October 2026 announcement of Fresenius’ acquisition of the remaining 45% of mAbxience is available here. The 31 March 2022 announcement of Fresenius Kabi’s acquisition of a 55% majority stake in mAbxience is available here, and the 1 August 2022 completion announcement here. The Biopharma ‘Meet the Management’ presentation of 15 December 2025 is available here. 

About polatuzumab vedotin  

Polatuzumab vedotin is an antibody-drug conjugate (ADC) marketed under the brand name Polivy® for the treatment large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma.¹  

Globally, DLBCL accounts for approximately one-third of non-Hodgkin lymphomas.² In 2024, more than 562,000 new cases of non-Hodgkin lymphoma were diagnosed worldwide, with approximately 235,000 deaths attributed to the disease.³  

The polatuzumab vedotin ADC comprises a monoclonal antibody directed against CD79b, a protein expressed on B cells including DLBCL cells, linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) through a cleavable linker. Following binding to CD79b, the ADC is internalized and MMAE is released, disrupting microtubules and leading to cell death.¹ 

Polivy® is administered by intravenous infusion and is a registered trademark of Genentech, Inc. 

About teprotumumab 

Teprotumumab is a human monoclonal antibody marketed under the brand name Tepezza® for the treatment of thyroid eye disease (TED), a rare autoimmune condition associated with Graves’ disease.⁴ TED is estimated to affect approximately 16 women and 3 men per 100,000 people annually, with around 25-50% of patients with Graves’ disease developing signs and symptoms of TED.⁵ 

Teprotumumab binds to and inhibits the insulin-like growth factor-1 receptor (IGF-1R), a receptor involved in cellular signaling pathways associated with the development and progression of TED. By inhibiting IGF-1R signaling, teprotumumab helps reduce the inflammatory and tissue-remodeling processes associated with the disease. Tepezza® is administered by intravenous infusion and is a registered trademark of Amgen Inc. 

About Fresenius 

Fresenius (XETR: FRE, OTCM: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450million peopleeach year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27million patientsannually. 

With more than178,000employees and operating in more than 60 countries, Fresenius generated €22.6billion in revenue in 2025.  

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.  

Press Contact:
Steffi Kim
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 175 3284 722
steffi.kim@fresenius.com

References 

[1] Polivy® (polatuzumab vedotin-piiq) U.S. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf [Last accessed October 2026]. 

[2] Wang, S. S. (2023) Epidemiology and Etiology of Diffuse Large B-Cell Lymphoma (DLBCL). Semin. Hematol. 60, 255–266.  

[3] International Agency for Research on Cancer. Global Cancer Observatory: Non-Hodgkin Lymphoma Fact Sheet, GLOBOCAN 2024. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf [Last accessed October 2026] 

[4] Tepezza® (teprotumumab-trbw) U.S. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761143s012lbl.pdf [Last accessed October 2026]. 

[5] Moledina, M., Damato, E. M. & Lee, V. (2024) The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye 38, 1425-37. 

Cautionary Statement on Forward-Looking Statements 

This release contains forward-looking statements that are subject to various risks and uncertainties including statements regarding the potential number of biosimilar candidates developed under the agreement with WuXi Biologics, the resulting pipeline size (including references to “up to 66” molecules), the timing and scope of any transfer of manufacturing to the mAbxience network, and Fresenius’ growth prospects beyond 2030. Whether, when and how many candidates are developed under the agreement remains subject to Fresenius’ future exercise of options on a candidate-by-candidate basis, and no assurance can be given that any, or all, of the identified candidates will be developed or will reach the market. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release. 

Fresenius SE & Co. KGaA 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852 
Chairman of the Supervisory Board: Wolfgang Kirsch 

General Partner: Fresenius Management SE 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673 
Management Board: Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,  
Dr. Michael Moser, Dr. Christian Pawlu   
Chairman of the Supervisory Board: Wolfgang Kirsch 

Media Information

SKAN Group AG informs about the proceedings by the Office of the Attorney General of Switzerland from 2023

Allschwil, 2 November 2026 – On 25 and 26 May 2023, SKAN Group AG announced in ad hoc releases that the Office of the Attorney General had launched an insider trading investigation against the then-Chairman of the Board of Directors and two employees. The proceedings against the former Chairman of the Board of Directors have since been dismissed. The Office of the Attorney General of Switzerland has dropped all allegations, with the state bearing the full cost of the proceedings.

The ongoing proceedings involve the CFO and the Head of the Services, Digital & Single-Use Systems segment. The trial on the charges brought by the Office of the Attorney General of Switzerland will take place on 5 November 2026 at the Federal Criminal Court, with the first-instance decision to be announced on 17 November 2026.

At the time the investigation was launched in 2023, the Board of Directors conducted a thorough assessment of the situation and expressed its confidence in both persons. This assessment remains valid. The Board of Directors upholds the presumption of innocence and is maintaining both persons in their functions.

SKAN Group AG has the greatest interest in the ongoing proceedings being concluded as quickly as possible and is cooperating closely with the authorities. As soon as the first-instance decision has been announced, SKAN Group AG will inform again.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, software, services and single-use systems. Innovative solutions and a customer-focused life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs around 1700 people. About half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.

This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country.

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

EvoNext Holdings SA and Ascend Sport Technology sign merger agreement. Share placement of up to CHF 220 million – EvoNext EGM to be held on December 3

• EvoNext Holdings SA (SIX: EVE) and Ascend Sport Technology AG have signed the merger agreement
• The transaction will include a share placement of up to CHF 220 million, targeting a free float of approximately 40%, comprising predominantly secondary shares and a smaller primary issuance to support future growth initiatives
• The Swiss sports technology holding company Ascend will become a publicly listed entity through a merger into EvoNext with its existing listing on SIX Swiss Exchange
• The company will commence investor pre-marketing (early-look meetings with institutional investors)
• EvoNext will hold an extraordinary general meeting (EGM) on December 3 to approve the transaction, which remains subject to decisions by the extraordinary general meetings of both companies
• Following the merger, current shareholders of EvoNext will hold approximately 3.8% of the combined entity
• The Offering price for share placement is expected to be CHF 2.50 per share
• Ascend is a Swiss sports technology holding company, bringing together complementary businesses across the sports technology value chain and forming a leading global platform with AI-enabled monetisation capabilities. Ascend serves over 100 rightsholders and more than 500 brands and broadcasters in over 20 countries

Reinach / Lucerne, Switzerland, 2 November 2026 – Following the announcement of a transaction agreement on 12 October 2026 EvoNext Holdings SA (“EvoNext”, SIX: EVE), a Swiss listed holding company, and Ascend Sport Technology AG (“Ascend”), a Swiss sports technology holding company, today announce the signing of the merger agreement. Subject to the approval of both companies’ general meetings, the statutory merger will lead to the formation of a listed Swiss sports technology company to operate under the name of Ascend Sport Technology AG and remain listed on the SIX Swiss Exchange.

Merger structure and valuation

Following the statutory merger (merging of Ascend business against issuance of new EvoNext shares) EvoNext will conduct a share placement (the “Offering”) totaling up to CHF 220 million incl. a 10% greenshoe of secondary shares, targeting a free float of approximately 40%. The Offering is expected to consist predominantly of secondary shares to create an attractive free float and establish a diversified institutional shareholder base, complemented by a primary issuance to support Ascend’s continued growth, strategic initiatives and general corporate purposes. The Offering price is expected to be CHF 2.50.

The former Ascend shareholders, members of management and members of the Board of Directors of the combined company, as well as certain EvoNext shareholders will be subject to lock-up arrangements subject to customary exceptions. 50% of the relevant shares will be subject to a 12‑month lock-up period following completion of the transaction, with the remaining 50% subject to a 24‑month lock-up period. Customary orderly market provisions will be in place.

Key figures and strategic guidance

Ascend is a Swiss sports technology holding company. The premium platform for the global sports technology market brings together complementary businesses across the sports technology value chain and forms a leading global platform with AI-enabled monetization capabilities. Ascend’s businesses serve over 100 rightsholders, including sports leagues, clubs and federations such as FIFA and UEFA, as well as more than 500 brands and broadcasters across over 20 countries. They are present in over 12 active top leagues worldwide – including the top five European leagues. 19 of Europe’s top 30 clubs are among their clients and to date over 10,000 matches have been supported by Ascend’s technology.

Ascend generated net revenues of ca. CHF 44 million for the Full Year 25/26 and EBITDA of ca. CHF 25 million – resulting in an attractive EBITDA margin of 57%.[1] The Company’s fiscal year starts on 1 July and ends on 30 June.

The Company’s medium-term target is to increase net revenues by 100% over a four-year period, reflecting the football tournament cycle. Growth will vary across the period due to major international competitions, which materially influence the timing of the revenue. Medium-term growth is supported by multiple structural drivers: increasing share of wallet with existing clients, new customer wins, expansion into new geographies, markets and sports, and continued adoption of its technology. For fiscal year 26/27 Ascend expects net revenue growth of ca. 10%, as the year marks the beginning of a new cycle with less revenue from international competitions.

In terms of profitability and over the medium term, the company aims for an EBITDA margin of ca. 50% driven by scale and an increasing contribution from higher margin Digital Overlay and marketplace revenues. For fiscal year 26/27 the Company expects EBITDA in line with 25/26 as a result of additional functions and costs required for a listed company.

The Company is headquartered in Lucerne and expects a stable tax rate going forward.

Net working capital in % of net revenues is expected to gradually decrease to ca. 30% in the medium-term from an expected range of 30-35% for fiscal year 26/27. In 25/26 the ratio was ca. 35%. The company expects capital expenditures in % of net revenues to gradually trend towards the mid-teens from an expected range of 20-24% in 26/27 after ca. 27% in 25/26. This reflects the lower capital intensity as the business scales, with absolute capex broadly in line with historical levels while leveraging hardware investments already made.

Currently, there is no dividend payout foreseen. The cash generated will be used to support organic growth, selective rights acquisition and a disciplined M&A strategy, focused on increasing market share as well as geographic and capability driven add-on acquisitions.

Extraordinary General Meeting of EvoNext and of Ascend will be held on 3 December 2026

The resolutions on the Merger will become effective only once shareholders of both companies have approved the merger agreement.

EvoNext Holdings SA will publish the invitation to the Extraordinary General Meeting (EGM) at the latest on 12 November 2026 in the Swiss Official Gazette of Commerce (SOGC) and also on the EvoNext Website. The EGM will be held on Thursday, 3 December 2026, at 10.00 a.m. CET in Zurich.

The Board of Directors of EvoNext unanimously recommends that shareholders approve the transaction. EvoNext will inform shareholders and the market of any material new developments in due course.

The Extraordinary General Meeting of Ascend is also expected to resolve on the approval of the merger agreement and the Merger on 3 December 2026.

Documentation relating to the merger, including the merger report, shareholder information and invites to the extraordinary general meetings is available to shareholders in accordance with applicable legal and regulatory requirements as announced today in the SOGC.

Contact for investors and media

EvoNext Holdings SA

investors@evonextholdings.com

susanne.muehlemann@lemongrass.agency / +41 79 223 70 81

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Moreover, financial information contained in this publication may be preliminary and unaudited.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which it is unlawful to do so.

^[1] 2025/2026 audit not yet completed

Media Release – ad hoc announcement pursuant to Art. 53 LR

Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 2 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional end result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The additional acceptance period of the Offer ended on 30 October 2026, at 4:00 p.m. Swiss time. According to the provisional end result as published by Samsung Peptide,

• the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 32,458,892 PolyPeptide shares in aggregate, corresponding to 97.99% of the issued share capital and voting rights of PolyPeptide (participation rate); and
• 32,350,302 PolyPeptide shares were tendered into the Offer until the end of the additional acceptance period of the Offer, corresponding to 97.66% of the issued share capital and voting rights of PolyPeptide and 97.98% of all PolyPeptide shares to which the Offer relates (success rate).

The end result that has been published today by Samsung Peptide is provisional and is available at https://samsungbiologics.com/offer. The definitive end result is expected to be published on 5 November 2026.

According to the provisional end result as published by Samsung Peptide, the Offer remains subject to certain remaining Offer conditions, including the receipt of regulatory approvals in certain jurisdictions.

In its provisional end result, Samsung postponed the settlement of the Offer in accordance with section B.7.3 (Period for which the Offer Conditions are in Force and Effect and Deferral) of the Offer Prospectus and confirmed that based on the current understanding of the regulatory approval procedures in various countries (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances) of the Offer Prospectus), the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the provisional end result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580 

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com 
T: +41 43 502 0580
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the provisional end result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

Birkenfeld, October 30, 2026

STRATEC SE, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard), today signed an agreement with a consortium of Indian investors for the sale of its subsidiary Diatron MI. The sale comprises all Diatron products in the fields of hematology and clinical chemistry. Diatron’s OEM business in molecular and immunodiagnostics was carved out prior to the sale and remains part of the STRATEC Group. The fixed purchase price amounts to € 10.0 million. In addition, earn-out payments have been agreed. Closing of the transaction is expected in the fourth quarter of 2026.

Based on current planning for the 2026 financial year, the sold business is expected to generate sales of around € 20.0 million and adjusted EBIT of around minus € 10.0 million. Due to the implementation of measures relating to the sale, STRATEC will recognize non-cash impairments of € 44.1 million in the third quarter of 2026. Furthermore, the sale is expected to result in a negative non-cash deconsolidation effect of between € 4.0 million and € 9.0 million in the fourth quarter of 2026.

The sales and earnings contributions from the divested business, as well as the impairments arising in connection with the transaction and the deconsolidation effect, will be retrospectively allocated to discontinued operations for the 2026 financial year. To account for the sale of this loss-bringing business and the company’s updated planning, the Board of Management is amending its guidance for the 2026 financial year as follows: Based on pro-forma sales (adjusted to exclude the sold business) of € 223.5 million for the 2025 financial year, STRATEC expects to generate stable to slightly higher sales on a constant-currency basis in the 2026 financial year. Following separation of the sold business from continuing operations, STRATEC is forecasting an adjusted EBIT margin of between 13.0% and 15.0% for the 2026 financial year (previously: around 10.0% prior to the separation). The sale also has implications for STRATEC’s medium-term targets as communicated at the beginning of the year. These are therefore no longer being upheld and will be updated at the latest upon publication of the 2026 Annual Report.

The quarterly statement for the first nine months of 2026 will be published on November 12, 2026. Based on the information available, STRATEC expects to report sales of € 164.9 million and an adjusted EBIT margin of 8.3% for the first nine months of 2026. Both key figures still include sales and operating earnings contributions from the sold business. The aforementioned earnings figures have been adjusted to exclude amortization arising from acquisitions-related purchase price allocations and other non-recurring items, including the impairments recognized.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com